Pfizer (PFE) Non-Current Assets (2009 - 2026)
Pfizer (PFE) posted quarterly Non-Current Assets of $165.2 billion for Q1 2026, up 1.86% year-over-year from $162.2 billion in Q1 2025, and up 4909.95% quarter-over-quarter from $3.3 billion in Q4 2025.
Pfizer (PFE) Non-Current Assets (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Non-Current Assets for 18 consecutive years, with $165.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 1.86% year-over-year to $165.2 billion; the TTM figure through Mar 2026 stood at $651.5 billion (down 6.29% YoY), while the FY2025 annual figure was $3.3 billion, up 2.3% from the prior year.
- Non-Current Assets advanced to $165.2 billion in Q1 2026 per PFE's latest filing, from $3.3 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $178.7 billion in Q1 2024 and bottomed at $3.0 billion in Q4 2023.
- Historically, Non-Current Assets has averaged $107.0 billion across 5 years, with a median of $145.9 billion in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets retreated 15.41% — and 2024, when it surged 376.95%.
- Pfizer's Non-Current Assets stood at $3.0 billion in 2022, then declined by 0.17% to $3.0 billion in 2023, then grew by 7.11% to $3.2 billion in 2024, then advanced by 2.3% to $3.3 billion in 2025, then jumped by 4909.95% to $165.2 billion in 2026.
- Business Quant data shows PFE's Non-Current Assets at $165.2 billion in Q1 2026, $3.3 billion in Q4 2025, and $161.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 159.77 Bn |
| Mar 29, 2026 | 165.18 Bn |
| Dec 31, 2025 | 3.30 Bn |
| Sep 28, 2025 | 161.81 Bn |
| Jun 29, 2025 | 162.39 Bn |
| Mar 30, 2025 | 162.17 Bn |
| Dec 31, 2024 | 3.22 Bn |
| Sep 29, 2024 | 176.25 Bn |
| Jun 30, 2024 | 178.18 Bn |
| Mar 31, 2024 | 178.68 Bn |
| Dec 31, 2023 | 3.01 Bn |
| Sep 30, 2023 | 36.95 Bn |
| Jul 2, 2023 | 146.82 Bn |
| Apr 2, 2023 | 145.92 Bn |
| Dec 31, 2022 | 3.01 Bn |
| Sep 30, 2022 | 35.20 Bn |
| Jul 3, 2022 | 127.82 Bn |
| Apr 3, 2022 | 129.42 Bn |
| Dec 31, 2021 | 3.56 Bn |
| Oct 3, 2021 | 39.45 Bn |